welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Prognostic Factors Affecting Duchenne Muscular Dystrophy
study id #: NCT03372655
condition: Duchenne Muscular Dystrophy
Determination of prognostic factors affecting ambulation of duchenne muscular dystrophy
mechanism of action: No pharmaceutical intervention
last updated: December 10, 2019
start date: January 1, 2018
estimated completion: January 1, 2019
size / enrollment: 82
Duchenne muscular dystrophy is the most common herditary muscular disease , it lead to loss of ambulation in early teenageers . It lead to early death at the mean age of 19 years
- Ten meter walking test [Time Frame: 2018 - 2019]
- Muscle strength [Time Frame: 2018- 2019]
• Eligible Sexes: male
Any male pt diagnosed as Duchenne muscular dystrophy by typical clinical picture & shooting serum CPK level & EMG study or biopsy & age 10 to 18yrs old
Female patient' age below 10 yrs old or above 18 yrs old. Patient with autoimmune disease or malignancy.
Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystro...Background: Duchenne muscular dystrophy...
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocortico...The purpose of the study is to assess th...
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular DystrophyThis study is single arm, single center ...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
Whole Body Vibration Therapy in Boys With Duchenne Muscular DystrophyWhole-body vibration therapy (WBVT) is a...
Lower Limb Flexibility in Duchenne Muscular Dystrophy: Effects on Functional PerformanceThe investigator investigated the effect...
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...